EU projects – Technology Scouting – Business Innovation

AMIRES at theNext-Gen OoC and Organoid Workshop

Our colleague Kristin Aldag from the Health & Biotech programme recently represented AMIRES in the Next Generation Organ-On-Chip & Organoids Workshop in Zürich! 
Organised by AMIRES long-term partner CSEM, the event held on 24-25 August 2023 brought together a dynamic mix of pharma and biotech industry, startups and academic groups in the Organ-on-Chip (OoC) and organoid field and we were happy to be among them!

AMIRES is active in the OoC and organoid field mainly with our projects Tumor-LN-oC and Organtrans.

The event was a fantastic opportunity to discover future directions of the research and innovation in this area and build new collaborations for future endeavours. Excellent speakers presented their groundbreaking research and results using OoC and organoid technologies. Panel discussions addressed cutting-edge advancements in the field and explored ways to accelerate the translation of these advanced in-vitro models from the lab into real-world industry and clinical applications, e.g. in personalised medicine and drug development. We also had the pleasure to connect with our partners from Elveflow, who were represented at the conference with a booth exhibiting their state-of-the-art microfluidic instruments. 

Our key takeaways from the workshop include the fact that OoC technology is the emerging state of the art in biomedical research and will play a determine role in the future. The field has progressed immensely in last 20 years, however many challenges remain which hinder or slow down the adoption on a large, industrial scale. These include the questions of standardisation / harmonisation of the technology for enhanced cross-compatibility, questions of validation and model qualification as well as regulatory acceptance. As a result, OoC are currently used and developed mainly on a smaller, experimental scale for research applications and are not yet accepted as a gold standard in large-scale industrial applications (e.g. drug development), or in clinical applications (e.g. personalised medicine, regenerative medicine). Neverhteless, there is a big European innovation ecosystem with many SMEs and startups active in the field and developing novel solutions for biomedical research, which result in a lot of innovation activities, demonstrating the huge potential for revolutionising drug development, disease research and personalised medicine. 

More insights and conclusions from the conference were presented to AMIRES colleagues in the monthly AMILecture. 
A big thank you to the organizers for putting together such an insightful and impactful event and the chance to be a part of the discussions! It was a great opportunity to exchange ideas, grow our partner network and gain valuable insights that will undoubtedly contribute to ongoing and future projects at AMIRES. We are looking forward to applying the knowledge gained and continuing to drive innovation in the Organ-on-Chip and organoid field with our projects!